Article
Oncology
Ken Kudura, Florentia Dimitriou, Lucas Basler, Robert Forster, Daniela Mihic-Probst, Tim Kutzker, Reinhard Dummer, Joanna Mangana, Irene A. Burger, Michael C. Kreissl
Summary: For melanoma patients undergoing immune checkpoint inhibition, FDG-PET/CT can predict early treatment response. SUV peak and volume variation of metastases are strong outcome predictive biomarkers on a metastasis-level. On a patient-level, total tumor volume and semiquantitative parameters of all metastases show promise as outcome predictive biomarkers.
Editorial Material
Medicine, General & Internal
Romain-David Seban, Camille Vermersch, Laurence Champion, Benjamin Bonsang, Anissa Roger, Jerome Ghidaglia
Summary: Early detection of immune-related adverse events (irAEs) is crucial with immune checkpoint inhibitors (ICIs), as they may mimic tumor progression. This case report highlights a 68-year-old woman who developed erythema nodosum - an immune-related sarcoid-like reaction - after receiving ICI treatment for metastatic melanoma. Nuclear medicine physicians should be aware of this irAE when interpreting PET/CT scans to avoid false-positive findings.
Article
Immunology
Karim Amrane, Coline Le Meur, Philippe Thuillier, Jacques Dzuko Kamga, Pierre Alemany, Frederic Chauvelot, Clemence Niel, Alex Bellange, Ronan Abgral
Summary: This study reports a very rare case of secondarily metastatic uveal melanoma with a dramatic response to pembrolizumab along with serial pseudogression. 18F-FDG-PET, clinical status, and dNLR were used as guidance for therapeutic strategy due to an atypical pseudoprogression phenomenon.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Gregor Schweighofer-Zwink, Reyhaneh Manafi-Farid, Peter Kolblinger, Lukas Hehenwarter, Sara Harsini, Christian Pirich, Mohsen Beheshti
Summary: This study evaluated the prognostic value of various metabolic parameters in 2-[F-18]FDG PET/CT scans for melanoma patients undergoing immunotherapy. The results showed that metabolic parameters in baseline and follow-up scans were predictive of 3- and 5-year overall survival rates. The 3-month follow-up scan was particularly important for prognosis assessment.
EUROPEAN JOURNAL OF RADIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Narjess Ayati, Zahra Jamshidi-Araghi, Magdalena Hoellwerth, Gregor Schweighofer-Zwink, Wolfgang Hitzl, Peter Koelblinger, Christian Pirich, Mohsen Beheshti
Summary: This study assessed tumor response in patients with metastatic melanoma treated with ICIs using three modified response criteria. Results showed that PERCIMT provided a more reliable assessment of disease control rate and overall patient survival.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Hemant Sachani, Sarthak Tripathy, Shamim Ahmed Shamim, Sameer Rastogi, Annie K. Baa
Summary: Melanomas typically occur in sun-exposed areas of the skin, with mucosal melanoma being a rare condition. Melanoma of the glans penis is even rarer, with fewer than 250 reported cases to date. We present a case of a 55-year-old man diagnosed with melanoma of the glans penis, with metastases detected in various lymph nodes on F-18 FDG PET/CT scan.
CLINICAL NUCLEAR MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Hongzhe Zhang, Yaping Luo
Summary: A 63-year-old man with a history of right plantar malignant melanoma developed multiple pulmonary metastases and a cardiac metastasis. F-18-FDG PET/CT was effective in detecting both pulmonary and cardiac metastases, as confirmed by dynamic myocardial perfusion MR.
Article
Radiology, Nuclear Medicine & Medical Imaging
Christos Sachpekidis, Annette Kopp-Schneider, Leyun Pan, Dimitrios Papamichail, Uwe Haberkorn, Jessica C. Hassel, Antonia Dimitrakopoulou-Strauss
Summary: This study aimed to investigate the prognostic role of [F-18]FDG PET/CT in predicting long-term outcomes to immunotherapy in metastatic melanoma. The results showed that PET/CT-based response to PD-1 blockade is significantly correlated with progression-free survival (PFS), highlighting its potential for early stratification of response to anti-PD-1 agents.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
JingXing Xiao, Min Su, Dong Wang
Summary: Primary malignant melanoma in the oropharynx is extremely rare, with this case report detailing a 49-year-old male presenting with progressive dysphagia. After undergoing total resection of the tumor, the patient showed no signs of recurrence after a 6-month follow-up.
CLINICAL NUCLEAR MEDICINE
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Ayah Adel Nawwar, Julie Searle, Iain Douglas Lyburn
Summary: A 58-year-old man with previous melanoma underwent PET/CT prior to starting pembrolizumab. After 3 months of treatment, PET/CT showed partial metabolic response and signs of thyroiditis and colitis. Stopping pembrolizumab led to resolution of the inflammatory changes.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Medicine, General & Internal
Virginia Liberini, Marco Rubatto, Riccardo Mimmo, Roberto Passera, Francesco Ceci, Paolo Fava, Luca Tonella, Giulia Polverari, Adriana Lesca, Marilena Bello, Vincenzo Arena, Simone Ribero, Pietro Quaglino, Desiree Deandreis
Summary: Higher values of whole-body and bone metabolic parameters were correlated with poorer outcome, while higher values of whole-body, lymph node and soft tissue metabolic parameters were correlated with OS.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Ken Kudura, Florentia Dimitriou, Daniela Mihic-Probst, Urs J. Muehlematter, Tim Kutzker, Lucas Basler, Robert Forster, Reinhard Dummer, Joanna Mangana, Lars Husmann, Irene A. Burger, Michael Christoph Kreissl
Summary: The use of FDG-PET/CT in metastatic melanoma patients has increased significantly due to improved survival rates. Indeterminate findings on FDG-PET/CT in these patients should be further investigated, as almost half of them are malignant with the majority being melanoma metastases. Other primary malignancies are also found in a significant proportion of cases, impacting clinical management in the majority of malignant findings.
Review
Medicine, General & Internal
Maria Mangas Losada, Leonardo Romero Robles, Alejandro Mendoza Melero, Irene Garcia Megias, Amos Villanueva Torres, Puy Garrastachu Zumaran, Xavier Boulvard Chollet, Egesta Lopci, Rafael Ramirez Lasanta, Roberto C. Delgado Bolton
Summary: Immunotherapy manipulates the immune system to target tumor cells, especially in melanoma patients. Challenges include finding evaluation criteria, identifying atypical response patterns, using PET biomarkers, and managing immunorelated adverse effects. This review focuses on the role of [F-18]FDG PET/CT in these challenges and its efficacy. Modified response criteria may be suitable for evaluating immunotherapy benefits, and [F-18]FDG PET/CT biomarkers show promise in predicting and assessing response. Immunorelated adverse effects can be early predictors of response and associated with better prognosis and benefit.
Article
Oncology
Kazuhiro Kitajima, Mitsunari Maruyama, Hiroyuki Yokoyama, Toshiyuki Minami, Takashi Yokoi, Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Kozo Kuribayashi, Takashi Kijima, Seiki Hasegawa, Koichiro Yamakado
Summary: This study compared three FDG-PET criteria (EORTC, PERCIST, imPERCIST) with CT criteria (combined modified RECIST and RECIST 1.1) for response evaluation and prognosis prediction in recurrent MPM patients treated with ICI therapy. The results showed that both FDG-PET and CT criteria are accurate for evaluating tumor response and predicting prognosis, with FDG-PET criteria identifying a greater percentage of patients as having complete metabolic response compared to CT criteria.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Mohadeseh Bayat, Abtin Doroudinia, Mehrdad Bakhshayesh Karam, Payam Mehrian
Summary: Immune checkpoint inhibitors have emerged as a novel treatment option for solid tumors, but they can cause immune-related adverse effects. This case report presents a 56-year-old woman with primary malignant melanoma who received nivolumab therapy. A posttreatment PET/CT scan showed increased metabolic activity in all major joints of her extremities, which was interpreted as an immune-related arthritis complication.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ray Ma, Alexandra McHaffie, Rathan M. Subramaniam, Megan Anakin
Summary: This study investigated the experience of students and educators in an integrated medical imaging curriculum. Findings suggest that the curriculum was perceived as being everywhere and nowhere, with repetitive and patchy teaching events emphasizing exposure and absorption. However, this integrated approach may lead to medical imaging losing visibility and importance as a distinct learning area.
ACADEMIC RADIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Brendan C. Stack Jr, Fenghai Duan, Justin Romanoff, JoRean D. Sicks, Rathan M. Subramaniam, Val J. Lowe
Summary: This study prospectively investigated the use of FDG PET/CT in 287 cN0 head and neck cancer patients, and analyzed the impact of neck FDG uptake on recurrence-free survival (RFS) and overall survival (OS). The results showed that visual assessment and SUVmax can be used to compare the effects of neck FDG uptake on RFS and OS.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Oncology
Emrullah Yilmaz, Nofisat Ismaila, Julie E. Bauman, Raetasha Dabney, Gregory Gan, Richard Jordan, Marnie Kaufman, Kedar Kirtane, Sean Matthew McBride, Matthew O. Old, Lisa Rooper, Nabil F. Saba, Siddharth Sheth, Rathan M. Subramaniam, Trisha Michel Wise-Draper, Deborah Wong, Loren K. Mell
Summary: The purpose of this study is to provide evidence-based recommendations for immunotherapy and biomarker testing in the treatment of head and neck cancers. A literature search was conducted to identify relevant studies, and a panel of experts developed evidence-based guideline recommendations based on the available evidence and consensus.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ajitha Ramesh, Aniruddha Chatterjee, Rathan M. Subramaniam
Article
Radiology, Nuclear Medicine & Medical Imaging
Asha Kandathil, Rathan M. Subramaniam
Article
Radiology, Nuclear Medicine & Medical Imaging
Hyesun Park, Rathan M. Subramaniam
Article
Radiology, Nuclear Medicine & Medical Imaging
Charles Marcus, Rathan M. Subramaniam
Article
Radiology, Nuclear Medicine & Medical Imaging
Grayson Wass, Kari Clifford, Rathan M. Subramaniam
Summary: This study evaluated the diagnostic performance of fibroblast-activation protein (FAP) PET/CT compared to 18F-FDG PET/CT in cancer. The results showed that FAP PET/CT had higher sensitivity in detecting primary lesions, nodal metastases, and distant metastases. Further studies are needed to assess its utility and indication in specific cancer types and clinical settings.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kit Chi Chan, Jose A. U. Perucho, Rathan M. Subramaniam, Elaine Y. P. Lee
Summary: This study aimed to evaluate the discriminative performance and predictive ability of texture features in determining lymph node involvement in cervical cancer using F-18-FDG PET/CT imaging. The results showed that PET-derived radiomic features had moderate performance in discriminating nodal involvement in cervical cancer, but did not outperform models based on conventional indices.
NUCLEAR MEDICINE COMMUNICATIONS
(2023)
Article
Medical Informatics
Benjamin H. Kann, Jirapat Likitlersuang, Dennis Bontempi, Zezhong Ye, Sanjay Aneja, Richard Bakst, Hillary R. Kelly, Amy F. Juliano, Sam Payabvash, Jeffrey P. Guenette, Ravindra Uppaluri, Danielle N. Margalit, Jonathan D. Schoenfeld, Roy B. Tishler, Robert Haddad, Hugo J. W. L. Aerts, Joaquin J. Garcia, Yael Flamand, Rathan M. Subramaniam, Barbara A. Burtness, Robert L. Ferris
Summary: This study evaluated a CT-based deep learning algorithm for predicting pathological extranodal extension (ENE) in patients with HPV-associated oropharyngeal carcinoma. The algorithm showed better performance than four board-certified head and neck radiologists in classifying ENE, suggesting its potential as a treatment selection tool.
LANCET DIGITAL HEALTH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jim Smith, Edward Barnett, Euan J. Rodger, Aniruddha Chatterjee, Rathan M. Subramaniam
Article
Radiology, Nuclear Medicine & Medical Imaging
Yasemin Sanli, Dilara Denizmen, Rathan M. Subramaniam
Summary: Lu-DOTA-TATE therapy is a highly effective treatment for metastatic, well-differentiated, SSTR-positive GEP-NETs with manageable side effects. PRRT is generally recommended as a second-line therapy after SSA for gastroenteric diseases, and as a second or third-line therapy for pancreatic NETs to improve survival rates and quality of life. Although more data is needed, Lu-DOTA-TATE therapy may also have a role in high-grade NET therapy, often in combination with chemotherapy. Liver-dominant metastatic disease usually has poor prognosis and requires liver-targeted therapies alone or in combination with PRRT based on the disease status.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Rathan M. Subramaniam
Article
Primary Health Care
Valerie Xiang, Sherly Parackal, Gagan Gurung, Rathan M. Subramaniam
Summary: This study aimed to investigate and analyze the resources available on general practice websites in New Zealand that aid in optimal health care navigation for Asians, and to explore the barriers perceived by Asian migrants to navigating the New Zealand Health System, particularly primary care. The study found that the analyzed general practice websites lack relevant and reliable information for Asians to effectively navigate the New Zealand health system. Participants reported significant difficulties in navigating and understanding New Zealand primary care services. Therefore, providing information resources in Asian languages as well as an overview of how Health NZ functions in providing health care and professional interpreter services would have a significant impact on increasing appropriate engagement with healthcare services and improving health outcomes for Asians.
JOURNAL OF PRIMARY HEALTH CARE
(2023)
Review
Oncology
Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi
Summary: Positron emission tomography (PET) imaging has made significant advancements in the diagnosis and treatment of prostate cancer with targeted radiopharmaceuticals. This review focuses on the commonly used PET radiopharmaceuticals in the USA, including prostate-specific membrane antigen (PSMA), fluciclovine, and choline. PET imaging has shown utility over traditional imaging methods in various scenarios, but there are limited studies comparing PET radiopharmaceuticals. PSMA radiopharmaceuticals have unique properties and uses, especially at low prostate-specific antigen (PSA) levels. The choice of PET radiopharmaceutical can impact image interpretation, as some agents have minimal urinary activity while others have high urinary activity.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
